Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFPIA Rejects EU Calls To Relax IP Protections

European Industry ‘Not Dependent On China & India’

Executive Summary

State-imposed mechanisms such as compulsory licensing will discourage rather than encourage investment in R&D, says Europe’s research-based industry. It has also dismissed suggestions that Europe is too dependent on API supplies from third countries.

You may also be interested in...



UK Committee Wants Compulsory Licensing To Secure Cheap COVID-19 Products

Some way needs to be found to guarantee the supply of coronavirus products as more of them begin to become available, but the pharmaceutical industry says compulsory licensing is not the answer.

EU Politicians Call For Compulsory Licensing, More Joint Procurement For COVID-19

A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.

EU Makes A United Bid For COVID-19 Vaccines

A new EU-wide strategy on procuring potential COVID-19 vaccines through advance purchase agreements has been launched, replacing earlier fragmented efforts by some member states. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel